AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00837434
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 mg dose of adalimumab by subcutaneous injection
Trial: NCT02275702
Drug: Dexamethasone IV
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It will be administered at the induction of the anesthesia
Trial: NCT02275702
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02367690
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical gel
Trial: NCT01077310
Drug: Vivitrol- Intramuscular naltrexone (depot-formulation)
RxNorm normalized name: naltrexone Injection [Vivitrol]
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Trial: NCT00070837
Drug: MLN2704 (DM1 conjugated monoclonal antibody MLN591)
RxNorm normalized name: Conjugated Estrogens
DrugBank: MLN2704 (DB06513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00198510
Drug: Vitrase
RxNorm normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 IU of Vitrase
Trial: NCT00198510
Drug: Vitrase
RxNorm normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 55 IU of Vitrase
Trial: NCT00198510
Drug: Vitrase
RxNorm normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 IU of Vitrase
Trial: NCT00527046
Drug: CP-424,391
RxNorm normalized name: CP-424,391
DrugBank: Capromorelin (DB15205)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01878786
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
Trial: NCT01878786
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
Trial: NCT01878786
Drug: Mycophenolate mofetil (MMF/MPA)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Control Drug
Trial: NCT01712763
Drug: degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 women will be treated with degarlix 120 mg, in only one administration covering three months
Trial: NCT01712763
Drug: Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 women will be treated with leuprolide acetate11.25 only once covering three months
Trial: NCT00772538
Drug: tiotropium 5mcg/day
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
Trial: NCT00436332
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01779830
Drug: Zolpidem - Tablets
RxNorm normalized name: zolpidem Oral Tablet
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally as tablets.
Trial: NCT01824238
Drug: Anacetrapib
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01824238
Drug: Placebo for anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00166803
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone , 4 mg daily
Trial: NCT00808132
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
Trial: NCT00808132
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
Trial: NCT00808132
Drug: bazedoxifene 20 mg
RxNorm normalized name: bazedoxifene 20 MG
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
Trial: NCT00808132
Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
Trial: NCT02497599
Drug: Indium-111-DOTA-Girentuximab-IRDye800CW
DrugBank: Girentuximab (DB05304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
Trial: NCT00270816
Drug: Interferon-ß-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
Trial: NCT00270816
Drug: Interferon ß-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 micrograms (8 MIU) administered subcutaneously (sc) every other day
Trial: NCT02405091
Drug: NBI-98854
RxNorm normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02470286
Drug: SA001 60mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Study Drug: SA001 60mg~* Comparator: Placebo~* Cohort 1 in the part 1 (Dose escalation study)
Trial: NCT01695941
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01695941
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT00531466
Drug: tolperisone HCl (AV650)
RxNorm normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally three times a day for 28 days
Trial: NCT00309361
Drug: Phentolamine Mesylate (NV-101)
RxNorm normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00404196
Drug: Calcipotriol and LEO80122 (LEO19123 cream)
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02470286
Drug: SA001 120mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Study Drug: SA001 120mg~* Comparator: Placebo~* Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)
Trial: NCT02470286
Drug: SA001 180mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Study Drug: SA001 180mg~* Comparator: Placebo~* Cohort 3 in the part 1 (Dose escalation study)
Trial: NCT00090324
Drug: quetiapine fumarate tablets
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02470286
Drug: SA001 240mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Study Drug: SA001 240mg~* Comparator: Placebo~* Cohort 4 in the part 1 (Dose escalation study)
Trial: NCT02470286
Drug: SA001 300mg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Study Drug: SA001 300mg~* Comparator: Placebo~* Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)
Trial: NCT03547908
Drug: DTG
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg tablet administered orally once daily, without regard to food
Trial: NCT03547908
Drug: F/TDF
RxNorm normalized name: Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200/300 mg tablet administered orally once daily, without regard to food
Trial: NCT02944110
Drug: Glucagon receptor antagonist LY2409021
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single oral dose of 300mg
Trial: NCT01001221
Drug: cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~* Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1
Trial: NCT01001221
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~* Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1.
Trial: NCT00000306
Drug: Dextroamphetamine
RxNorm normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03216564
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active vitamin D (Calcitriol) 0.25 micrograms
Trial: NCT01098435
Drug: RDC-0313 (ALKS 33)
RxNorm normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for daily oral administration
Trial: NCT03177317
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle.
Trial: NCT03346538
Drug: Continuous infusion low-dose MCI-186
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous injection
Trial: NCT00247962
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg
Trial: NCT00247962
Drug: sulphasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
Trial: NCT00770263
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00770263
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02963194
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00841854
Drug: pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pantoprazole 40mg bid
Trial: NCT00841854
Drug: bismuth
RxNorm normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bismuth 300mg qid
Trial: NCT00841854
Drug: metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metronidazole 500mg tid
Trial: NCT01849289
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
Trial: NCT01849289
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
Trial: NCT02142075
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00352027
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
Trial: NCT00352027
Drug: Nitrogen Mustard
RxNorm normalized name: Nitrogen mustard
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
Trial: NCT00352027
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Trial: NCT00352027
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Trial: NCT00352027
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV on Days 1 and 2 of weeks 1-10.
Trial: NCT00352027
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO every other day of weeks 1-12.
Trial: NCT01536886
Drug: Betamethasone plus calcipotriol
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00596622
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
Trial: NCT04723342
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment
Trial: NCT01968629
Drug: Eovist
RxNorm normalized name: Eovist
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02872090
Drug: Indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: inhalation
Trial: NCT02872090
Drug: Glycopyrronium
RxNorm normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation
Trial: NCT02872090
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation
Trial: NCT01371721
Drug: DVS SR
RxNorm normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: SRP-6004 (DB16998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
Trial: NCT00052494
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00052494
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00052494
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01813149
Drug: phenylephrine and clonidine
RxNorm normalized name: Clonidine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
Trial: NCT00928642
Drug: imatinib mesylate by mouth
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
Trial: NCT00928642
Drug: Gemcitabine Intravenous
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
Trial: NCT00086164
Drug: edifoligide (E2F Decoy)
RxNorm normalized name: Edifoligide
DrugBank: Edifoligide (DB06556)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04541043
Drug: Nefecon 16mg daily
RxNorm normalized name: futibatinib
DrugBank: Futibatinib (DB15149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All study patients received Nefecon 16 mg daily for 9 months.
Trial: NCT03698695
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/d and Mefloquine placebo
Trial: NCT03770936
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg/day
Trial: NCT03770936
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ramipril 1.25 mg/day
Trial: NCT03700424
Drug: Trehalose
RxNorm normalized name: Trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
Trial: NCT01420523
Drug: Raltegravir-Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
Trial: NCT01353976
Drug: Econazole Nitrate Foam 1%
DrugBank: Econazole (DB01127)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Econazole Nitrate Foam 1% applied once a day for 4 weeks
Trial: NCT03445780
Drug: Ethyl chloride spray
RxNorm normalized name: ethyl chloride Topical Spray
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin cooling with ethyl chloride spray 5 seconds prior to injection
Trial: NCT01553084
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
Trial: NCT01586013
Drug: evaluation of propofol effect using BIS
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol administered in target controlled infusion using the pharmacokinetic model of White
Trial: NCT00673075
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
Trial: NCT00673075
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily